Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE.
Portacci A, et al. Among authors: carpagnano ge.
ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep.
ERJ Open Res. 2023.
PMID: 37908397
Free PMC article.